Gravitas Collective Corp. has made a noteworthy move by reporting a significant ownership change in Hepion Pharmaceuticals, Inc. The filing reveals that Gravitas now holds 25 million shares of common stock in Hepion, marking a direct ownership stake. This development is important as it positions Gravitas as a director within Hepion, which could influence the company's future strategies and operations.
Gravitas Collective Corp. is incorporated in Delaware and is based in Red Bank, New Jersey. The company is categorized under the SIC code for pharmaceutical preparations. Its recent filings include a Form 3 submitted on October 21, 2026, and a Schedule 13D filed shortly after on October 26, 2026.
The recent filing indicates that Gravitas Collective Corp. has acquired a substantial number of shares in Hepion Pharmaceuticals. The filing states, "Gravitas Collective Corp. now owns 25 million shares of common stock in Hepion Pharmaceuticals, Inc." This ownership change is significant for both companies involved.
This change may affect various stakeholders, particularly those involved in the pharmaceutical preparations industry. As Gravitas increases its stake in Hepion, it may lead to shifts in management strategies, partnerships, or even new product developments. Competitors in the pharmaceutical sector will likely monitor this situation closely to gauge its potential impact on the market.
The filing does not specify what steps will be taken next following this ownership change. However, it does highlight the growing influence of Gravitas within Hepion Pharmaceuticals, suggesting that further developments may be on the horizon.